Peer-reviewed Publications

← Back to Publications

Peer-reviewed research contributions

This list was last updated on 2026-06-05.

  1. Entezari M, Ghanbarirad M, Taheriazam A, Sadrkhanloo M, Zabolian A, Goharrizi MASB, Hushmandi K, Aref AR, Ashrafizadeh M, Zarrabi A, Nabavi N, Rabiee N, Hashemi M, Samarghandian S. Corrigendum to “Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling” [Biomed. Pharmacother. 150 (2022) 112963].. Biomed Pharmacother. 2026 May;198:119309. doi: 10.1016/j.biopha.2026.119309. DOI
  2. Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, Rezaei S, Ren J, Nabavi N, Khorrami R, Rashidi M, Hushmandi K, Entezari M, Taheriazam A. Retraction notice to “Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies” [Biomedicine & Pharmacotherapy 160 (2023) 114392].. Biomed Pharmacother. 2026 May;198:119216. doi: 10.1016/j.biopha.2026.119216. DOI
  3. Tian Y, Tang M, Qiao M, Wang X, Huang Y, Luo T, Nabavi N, Ashrafizadeh M, Cheng H, Tu Y. STAT3-driven EMT in cancer metastasis and chemoresistance: A review.. Int J Biol Macromol. 2026 Apr;357:151403. doi: 10.1016/j.ijbiomac.2026.151403. DOI
  4. Yan Y, Liu S, Wen J, He Y, Duan C, Nabavi N, Ashrafizadeh M, Sethi G, Liu L, Ma R. Advances in RNA-based cancer therapeutics: pre-clinical and clinical implications.. Mol Cancer. 2025 Oct 09;24(1):251. doi: 10.1186/s12943-025-02463-y. DOI
  5. Jiang Y, Zhou Y, Tian Y, Nabavi N, Ashrafizadeh M, Conde J, Li Z, Guo L. Conductive polymers in smart wound healing: From bioelectric stimulation to regenerative therapies.. Mater Today Bio. 2025 Oct;34:102114. doi: 10.1016/j.mtbio.2025.102114. DOI
  6. Luo W, Shi Q, Han M, Zhang Z, Reiter RJ, Ashrafizadeh M, Nabavi N, Sethi G, Nicot C, Mao Y. TGF-<U+03B2>-driven EMT in cancer progression and drug resistance.. Cytokine Growth Factor Rev. 2025 Oct;85:11-25. doi: 10.1016/j.cytogfr.2025.05.004. DOI
  7. Hashemi M, Gholamrezaie H, Ziyaei F, Asadi S, Naeini ZY, Salimian N, Enayat G, Sharifi N, Aliahmadi M, Rezaie YS, Khoushab S, Rahimzadeh P, Miri H, Abedi M, Farahani N, Taheriazam A, Nabavi N, Entezari M. Role of lncRNA PVT1 in the progression of urological cancers: Novel insights into signaling pathways and clinical opportunities.. Cell Signal. 2025 Jul;131:111736. doi: 10.1016/j.cellsig.2025.111736. DOI
  8. Kahkesh S, Hedayati N, Rahimzadeh P, Farahani N, Khoozani MF, Abedi M, Nabavi N, Naeimi B, Khoshnazar SM, Alimohammadi M, Alaei E, Mahmoodieh B. The function of circular RNAs in regulating Wnt/<U+03B2>-catenin signaling: An innovative therapeutic strategy for breast and gynecological cancers.. Pathol Res Pract. 2025 Jun;270:155944. doi: 10.1016/j.prp.2025.155944. DOI
  9. Hushmandi K, Imani Fooladi AA, Reiter RJ, Farahani N, Liang L, Aref AR, Nabavi N, Alimohammadi M, Liu L, Sethi G. Next-generation immunotherapeutic approaches for blood cancers: Exploring the efficacy of CAR-T and cancer vaccines.. Exp Hematol Oncol. 2025 May 17;14(1):75. doi: 10.1186/s40164-025-00662-3. DOI
  10. Zhang M, Liu C, Tu J, Tang M, Ashrafizadeh M, Nabavi N, Sethi G, Zhao P, Liu S. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions.. Mol Cancer. 2025 May 07;24(1):136. doi: 10.1186/s12943-025-02305-x. DOI
  11. Miri H, Rahimzadeh P, Hashemi M, Nabavi N, Aref AR, Daneshi S, Razzaghi A, Abedi M, Tahmasebi S, Farahani N, Taheriazam A. Harnessing immunotherapy for hepatocellular carcinoma: Principles and emerging promises.. Pathol Res Pract. 2025 May;269:155928. doi: 10.1016/j.prp.2025.155928. DOI
  12. Alaei E, Hashemi F, Farahani N, Tahmasebi S, Nabavi N, Daneshi S, Mahmoodieh B, Rahimzadeh P, Taheriazam A, Hashemi M. Peptides in breast cancer therapy: From mechanisms to emerging drug delivery and immunotherapy strategies.. Pathol Res Pract. 2025 May;269:155946. doi: 10.1016/j.prp.2025.155946. DOI
  13. Hashemi M, Fard AA, Pakshad B, Asheghabadi PS, Hosseinkhani A, Hosseini AS, Moradi P, Mohammadbeygi Niye M, Najafi G, Farahzadi M, Khoushab S, Taheriazam A, Farahani N, Mohammadi M, Daneshi S, Nabavi N, Entezari M. Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: Recent insights and potential clinical applications.. Noncoding RNA Res. 2025 Apr;11:1-21. doi: 10.1016/j.ncrna.2024.11.006. DOI
  14. Hushmandi K, Alimohammadi M, Heiat M, Hashemi M, Nabavi N, Tabari T, Raei M, Aref AR, Farahani N, Daneshi S, Taheriazam A. Targeting Wnt signaling in cancer drug resistance: Insights from pre-clinical and clinical research.. Pathol Res Pract. 2025 Mar;267:155837. doi: 10.1016/j.prp.2025.155837. DOI
  15. Doodmani SM, Safari MH, Akbari M, Farahani N, Alimohammadi M, Aref AR, Tajik F, Maghsoodlou A, Daneshi S, Tabari T, Taheriazam A, Entezari M, Nabavi N, Hashemi M. Metastasis and chemoresistance in breast cancer: Crucial function of ZEB1/2 proteins.. Pathol Res Pract. 2025 Mar;267:155838. doi: 10.1016/j.prp.2025.155838. DOI
  16. Hashemi M, Khosroshahi EM, Daneii P, Hassanpoor A, Eslami M, Koohpar ZK, Asadi S, Zabihi A, Jamali B, Ghorbani A, Nabavi N, Memarkashani MR, Salimimoghadam S, Taheriazam A, Tan SC, Entezari M, Farahani N, Hushmandi K. Emerging roles of CircRNA-miRNA networks in cancer development and therapeutic response.. Noncoding RNA Res. 2025 Feb;10:98-115. doi: 10.1016/j.ncrna.2024.09.006. DOI
  17. Hashemi M, Mohandesi Khosroshahi E, Asadi S, Tanha M, Ghatei Mohseni F, Abdolmohammad Sagha R, Taheri E, Vazayefi P, Shekarriz H, Habibi F, Mortazi S, Khorrami R, Nabavi N, Rashidi M, Taheriazam A, Rahimzadeh P, Entezari M. Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer.. Noncoding RNA Res. 2025 Feb;10:1-15. doi: 10.1016/j.ncrna.2024.08.002. DOI
  18. Farahani N, Alimohammadi M, Raei M, Nabavi N, Aref AR, Hushmandi K, Daneshi S, Razzaghi A, Taheriazam A, Hashemi M. Exploring the dual role of endoplasmic reticulum stress in urological cancers: Implications for tumor progression and cell death interactions.. J Cell Commun Signal. 2024 Dec;18(4):e12054. doi: 10.1002/ccs3.12054. DOI
  19. Hashemi M, Rezaei M, Rezaeiaghdam H, Jamali B, Koohpar ZK, Tanha M, Bizhanpour A, Asadi S, Jafari AM, Khosroshahi EM, Eslami M, Salimimoghadam S, Nabavi N, Rashidi M, Fattah E, Taheriazam A, Entezari M. Highlighting function of Wnt signalling in urological cancers: Molecular interactions, therapeutic strategies, and (nano)strategies.. Transl Oncol. 2024 Dec;50:102145. doi: 10.1016/j.tranon.2024.102145. DOI
  20. Hushmandi K, Klionsky DJ, Aref AR, Bonyadi M, Reiter RJ, Nabavi N, Salimimoghadam S, Saadat SH. Ferroptosis contributes to the progression of female-specific neoplasms, from breast cancer to gynecological malignancies in a manner regulated by non-coding RNAs: Mechanistic implications.. Noncoding RNA Res. 2024 Dec;9(4):1159-1177. doi: 10.1016/j.ncrna.2024.05.008. DOI
  21. Hushmandi K, Einollahi B, Aow R, Suhairi SB, Klionsky DJ, Aref AR, Reiter RJ, Makvandi P, Rabiee N, Xu Y, Nabavi N, Saadat SH, Farahani N, Kumar AP. Investigating the interplay between mitophagy and diabetic neuropathy: Uncovering the hidden secrets of the disease pathology.. Pharmacol Res. 2024 Oct;208:107394. doi: 10.1016/j.phrs.2024.107394. DOI
  22. Hedayati N, Mafi A, Farahani A, Hashemi M, Nabavi N, Alimohammadi M, Rahimzadeh P, Taheriazam A, Farahani N. The importance of the circRNA/Wnt axis in gliomas: Biological functions and clinical opportunities.. Pathol Res Pract. 2024 Sep;261:155510. doi: 10.1016/j.prp.2024.155510. DOI
  23. Hedayati N, Safaei Naeini M, Ale Sahebfosoul MM, Mafi A, Eshaghi Milasi Y, Rizaneh A, Nabavi N, Farahani N, Alimohammadi M, Ghezelbash B. MicroRNA dysregulation and its impact on apoptosis-related signaling pathways in myelodysplastic syndrome.. Pathol Res Pract. 2024 Sep;261:155478. doi: 10.1016/j.prp.2024.155478. DOI
  24. Mafi A, Hedayati N, Milasi YE, Kahkesh S, Daviran M, Farahani N, Hashemi M, Nabavi N, Alimohammadi M, Rahimzadeh P, Taheriazam A. The function and mechanism of circRNAs in 5-fluorouracil resistance in tumors: Biological mechanisms and future potential.. Pathol Res Pract. 2024 Aug;260:155457. doi: 10.1016/j.prp.2024.155457. DOI
  25. Shakeri M, Aminian A, Mokhtari K, Bahaeddini M, Tabrizian P, Farahani N, Nabavi N, Hashemi M. Unraveling the molecular landscape of osteoarthritis: A comprehensive review focused on the role of non-coding RNAs.. Pathol Res Pract. 2024 Aug;260:155446. doi: 10.1016/j.prp.2024.155446. DOI
  26. Mafi A, Khoshnazar SM, Shahpar A, Nabavi N, Hedayati N, Alimohammadi M, Hashemi M, Taheriazam A, Farahani N. Mechanistic insights into circRNA-mediated regulation of PI3K signaling pathway in glioma progression.. Pathol Res Pract. 2024 Aug;260:155442. doi: 10.1016/j.prp.2024.155442. DOI
  27. Alimohammadi M, Rahimzadeh P, Khorrami R, Bonyadi M, Daneshi S, Nabavi N, Raesi R, Farani MR, Dehkhoda F, Taheriazam A, Hashemi M. A comprehensive review of the PTEN/PI3K/Akt axis in multiple myeloma: From molecular interactions to potential therapeutic targets.. Pathol Res Pract. 2024 Aug;260:155401. doi: 10.1016/j.prp.2024.155401. DOI
  28. Hushmandi K, Saadat SH, Mirilavasani S, Daneshi S, Aref AR, Nabavi N, Raesi R, Taheriazam A, Hashemi M. The multifaceted role of SOX2 in breast and lung cancer dynamics.. Pathol Res Pract. 2024 Aug;260:155386. doi: 10.1016/j.prp.2024.155386. DOI
  29. Hashemi M, Khosroshahi EM, Chegini MK, Asadi S, Hamyani Z, Jafari YA, Rezaei F, Eskadehi RK, Kojoori KK, Jamshidian F, Nabavi N, Alimohammadi M, Rashidi M, Mahmoodieh B, Khorrami R, Taheriazam A, Entezari M. Mechanistic insights into cisplatin response in breast tumors: Molecular determinants and drug/nanotechnology-based therapeutic opportunities.. Mutat Res Rev Mutat Res. 2024;794:108513. doi: 10.1016/j.mrrev.2024.108513. DOI
  30. Hushmandi K, Saadat SH, Raei M, Aref AR, Reiter RJ, Nabavi N, Taheriazam A, Hashemi M. The science of exosomes: Understanding their formation, capture, and role in cellular communication.. Pathol Res Pract. 2024 Jul;259:155388. doi: 10.1016/j.prp.2024.155388. DOI
  31. Hushmandi K, Saadat SH, Raei M, Daneshi S, Aref AR, Nabavi N, Taheriazam A, Hashemi M. Implications of c-Myc in the pathogenesis and treatment efficacy of urological cancers.. Pathol Res Pract. 2024 Jul;259:155381. doi: 10.1016/j.prp.2024.155381. DOI
  32. Samaei SS, Daryab M, Gholami S, Rezaee A, Fatehi N, Roshannia R, Hashemi S, Javani N, Rahmanian P, Amani-Beni R, Zandieh MA, Nabavi N, Rashidi M, Malgard N, Hashemi M, Taheriazam A. Multifunctional and stimuli-responsive liposomes in hepatocellular carcinoma diagnosis and therapy.. Transl Oncol. 2024 Jul;45:101975. doi: 10.1016/j.tranon.2024.101975. DOI
  33. Hushmandi K, Einollahi B, Saadat SH, Lee EHC, Farani MR, Okina E, Huh YS, Nabavi N, Salimimoghadam S, Kumar AP. Amino acid transporters within the solute carrier superfamily: Underappreciated proteins and novel opportunities for cancer therapy.. Mol Metab. 2024 Jun;84:101952. doi: 10.1016/j.molmet.2024.101952. DOI
  34. Hashem M, Mohandesi Khosroshahi E, Aliahmady M, Ghanei M, Soofi Rezaie Y, Alsadat Jafari Y, Rezaei F, Khodaparast Eskadehi R, Kia Kojoori K, Jamshidian F, Nabavi N, Rashidi M, Hasani Sadi F, Taheriazam A, Entezari M. Non-coding RNA transcripts, incredible modulators of cisplatin chemo-resistance in bladder cancer through operating a broad spectrum of cellular processes and signaling mechanism.. Noncoding RNA Res. 2024 Jun;9(2):560-582. doi: 10.1016/j.ncrna.2024.01.009. DOI
  35. Rezaee A, Rahmanian P, Nemati A, Sohrabifard F, Karimi F, Elahinia A, Ranjbarpazuki A, Lashkarbolouki R, Dezfulian S, Zandieh MA, Salimimoghadam S, Nabavi N, Rashidi M, Taheriazam A, Hashemi M, Hushmandi K. NF-<U+0138>B axis in diabetic neuropathy, cardiomyopathy and nephropathy: A roadmap from molecular intervention to therapeutic strategies.. Heliyon. 2024 May 15;10(9):e29871. doi: 10.1016/j.heliyon.2024.e29871. DOI
  36. Ashrafizadeh M, Dai J, Torabian P, Nabavi N, Aref AR, Aljabali AAA, Tambuwala M, Zhu M. Circular RNAs in EMT-driven metastasis regulation: modulation of cancer cell plasticity, tumorigenesis and therapy resistance.. Cell Mol Life Sci. 2024 May 11;81(1):214. doi: 10.1007/s00018-024-05236-w. DOI
  37. Hashemi M, Daneii P, Asadalizadeh M, Tabari K, Matinahmadi A, Bidoki SS, Motlagh YSM, Jafari AM, Ghorbani A, Dehghanpour A, Nabavi N, Tan SC, Rashidi M, Taheriazam A, Entezari M, Goharrizi MASB. Epigenetic regulation of hepatocellular carcinoma progression: MicroRNAs as therapeutic, diagnostic and prognostic factors.. Int J Biochem Cell Biol. 2024 May;170:106566. doi: 10.1016/j.biocel.2024.106566. DOI
  38. Ebrahimi N, Manavi MS, Faghihkhorasani F, Fakhr SS, Baei FJ, Khorasani FF, Zare MM, Far NP, Rezaei-Tazangi F, Ren J, Reiter RJ, Nabavi N, Aref AR, Chen C, Ertas YN, Lu Q. Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response.. Cancer Metastasis Rev. 2024 Mar;43(1):457-479. doi: 10.1007/s10555-023-10162-7. DOI
  39. Hashemi M, Esbati N, Rashidi M, Gholami S, Raesi R, Bidoki SS, Goharrizi MASB, Motlagh YSM, Khorrami R, Tavakolpournegari A, Nabavi N, Zou R, Mohammadnahal L, Entezari M, Taheriazam A, Hushmandi K. Biological landscape and nanostructural view in development and reversal of oxaliplatin resistance in colorectal cancer.. Transl Oncol. 2024 Feb;40:101846. doi: 10.1016/j.tranon.2023.101846. DOI
  40. Baniasadi M, Talebi S, Mokhtari K, Zabolian AH, Khosroshahi EM, Entezari M, Dehkhoda F, Nabavi N, Hashemi M. Role of non-coding RNAs in osteoporosis.. Pathol Res Pract. 2024 Jan;253:155036. doi: 10.1016/j.prp.2023.155036. DOI
  41. Karimi B, Mokhtari K, Rozbahani H, Peymani M, Nabavi N, Entezari M, Rashidi M, Taheriazam A, Ghaedi K, Hashemi M. Pathological roles of miRNAs and pseudogene-derived lncRNAs in human cancers, and their comparison as prognosis/diagnosis biomarkers.. Pathol Res Pract. 2024 Jan;253:155014. doi: 10.1016/j.prp.2023.155014. DOI
  42. Hashemi M, Nazdari N, Gholamiyan G, Paskeh MDA, Jafari AM, Nemati F, Khodaei E, Abyari G, Behdadfar N, Raei B, Raesi R, Nabavi N, Hu P, Rashidi M, Taheriazam A, Entezari M. EZH2 as a potential therapeutic target for gastrointestinal cancers.. Pathol Res Pract. 2024 Jan;253:154988. doi: 10.1016/j.prp.2023.154988. DOI
  43. Yenki P, Bhasin S, Liu L, Nabavi N, Cheng CW, Tam KJ, Peacock JW, Adomat HH, Tombe T, Fazli L, Ivanova L, Dusek C, Khosravi S, Guns EST, Wang Y, Buttyan R, Gleave ME, Ong CJ. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells.. Endocr Relat Cancer. 2023 Dec 01;30(12). doi: 10.1530/ERC-23-0010. DOI
  44. Tehrany PM, Rahmanian P, Rezaee A, Ranjbarpazuki G, Sohrabi Fard F, Asadollah Salmanpour Y, Zandieh MA, Ranjbarpazuki A, Asghari S, Javani N, Nabavi N, Aref AR, Hashemi M, Rashidi M, Taheriazam A, Motahari A, Hushmandi K. Multifunctional and theranostic hydrogels for wound healing acceleration: An emphasis on diabetic-related chronic wounds.. Environ Res. 2023 Dec 01;238(Pt 1):117087. doi: 10.1016/j.envres.2023.117087. DOI
  45. Sadeghi MS, Sangrizeh FH, Jahani N, Abedin MS, Chaleshgari S, Ardakan AK, Baeelashaki R, Ranjbarpazuki G, Rahmanian P, Zandieh MA, Nabavi N, Aref AR, Salimimoghadam S, Rashidi M, Rezaee A, Hushmandi K. Graphene oxide nanoarchitectures in cancer therapy: Drug and gene delivery, phototherapy, immunotherapy, and vaccine development.. Environ Res. 2023 Nov 15;237(Pt 2):117027. doi: 10.1016/j.envres.2023.117027. DOI
  46. Hashemi M, Khosroshahi EM, Chegini MK, Abedi M, Matinahmadi A, Hosnarody YSD, Rezaei M, Saghari Y, Fattah E, Abdi S, Entezari M, Nabavi N, Rashidi M, Raesi R, Taheriazam A. miRNAs and exosomal miRNAs in lung cancer: New emerging players in tumor progression and therapy response.. Pathol Res Pract. 2023 Nov;251:154906. doi: 10.1016/j.prp.2023.154906. DOI
  47. Sadrkhanloo M, Paskeh MDA, Hashemi M, Raesi R, Bahonar A, Nakhaee Z, Entezari M, Beig Goharrizi MAS, Salimimoghadam S, Ren J, Nabavi N, Rashidi M, Dehkhoda F, Taheriazam A, Tan SC, Hushmandi K. New emerging targets in osteosarcoma therapy: PTEN and PI3K/Akt crosstalk in carcinogenesis.. Pathol Res Pract. 2023 Nov;251:154902. doi: 10.1016/j.prp.2023.154902. DOI
  48. Hashemi M, Razzazan M, Bagheri M, Asadi S, Jamali B, Khalafi M, Azimi A, Rad S, Behroozaghdam M, Nabavi N, Rashidi M, Dehkhoda F, Taheriazam A, Entezari M. Versatile function of AMPK signaling in osteosarcoma: An old player with new emerging carcinogenic functions.. Pathol Res Pract. 2023 Nov;251:154849. doi: 10.1016/j.prp.2023.154849. DOI
  49. Zandieh MA, Farahani MH, Daryab M, Motahari A, Gholami S, Salmani F, Karimi F, Samaei SS, Rezaee A, Rahmanian P, Khorrami R, Salimimoghadam S, Nabavi N, Zou R, Sethi G, Rashidi M, Hushmandi K. Stimuli-responsive (nano)architectures for phytochemical delivery in cancer therapy.. Biomed Pharmacother. 2023 Oct;166:115283. doi: 10.1016/j.biopha.2023.115283. DOI
  50. Rezaei S, Nikpanjeh N, Rezaee A, Gholami S, Hashemipour R, Biavarz N, Yousefi F, Tashakori A, Salmani F, Rajabi R, Khorrami R, Nabavi N, Ren J, Salimimoghadam S, Rashidi M, Zandieh MA, Hushmandi K, Wang Y. PI3K/Akt signaling in urological cancers: Tumorigenesis function, therapeutic potential, and therapy response regulation.. Eur J Pharmacol. 2023 Sep 15;955:175909. doi: 10.1016/j.ejphar.2023.175909. DOI
  51. Hashemi M, Abbaszadeh S, Rashidi M, Amini N, Talebi Anaraki K, Motahhary M, Khalilipouya E, Harif Nashtifani A, Shafiei S, Ramezani Farani M, Nabavi N, Salimimoghadam S, Aref AR, Raesi R, Taheriazam A, Entezari M, Zha W. STAT3 as a newly emerging target in colorectal cancer therapy: Tumorigenesis, therapy response, and pharmacological/nanoplatform strategies.. Environ Res. 2023 Sep 15;233:116458. doi: 10.1016/j.envres.2023.116458. DOI
  52. Rezaee A, Tehrany PM, Tirabadi FJ, Sanadgol N, Karimi AS, Ajdari A, Eydivandi S, Etemad S, Rajabi R, Rahmanian P, Khorrami R, Nabavi N, Aref AR, Fan X, Zou R, Rashidi M, Zandieh MA, Hushmandi K. Epigenetic regulation of temozolomide resistance in human cancers with an emphasis on brain tumors: Function of non-coding RNAs.. Biomed Pharmacother. 2023 Sep;165:115187. doi: 10.1016/j.biopha.2023.115187. DOI
  53. Hashemi M, Gholami S, Raesi R, Sarhangi S, Mahmoodieh B, Koohpar ZK, Goharrizi MASB, Behroozaghdam M, Entezari M, Salimimoghadam S, Zha W, Rashidi M, Abdi S, Taheriazam A, Nabavi N. Biological and therapeutic viewpoints towards role of miR-218 in human cancers: Revisiting molecular interactions and future clinical translations.. Cell Signal. 2023 Sep;109:110786. doi: 10.1016/j.cellsig.2023.110786. DOI
  54. Al-Rashidi RR, Noraldeen SAM, Kareem AK, Mahmoud AK, Kadhum WR, Ram<U+00ED>rez-Coronel AA, Iswanto AH, Obaid RF, Jalil AT, Mustafa YF, Nabavi N, Wang Y, Wang L. Malignant function of nuclear factor-kappaB axis in prostate cancer: Molecular interactions and regulation by non-coding RNAs.. Pharmacol Res. 2023 Aug;194:106775. doi: 10.1016/j.phrs.2023.106775. DOI
  55. Karimi K, Mojtabavi S, Tehrany PM, Nejad MM, Rezaee A, Mohtashamian S, Hamedi E, Yousefi F, Salmani F, Zandieh MA, Nabavi N, Rabiee N, Ertas YN, Salimimoghadam S, Rashidi M, Rahmanian P, Hushmandi K, Yu W. Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: Versatile bio-platform with theranostic application.. Int J Biol Macromol. 2023 Jul 01;242(Pt 3):124935. doi: 10.1016/j.ijbiomac.2023.124935. DOI
  56. Ebrahimi N, Far NP, Fakhr SS, Faghihkhorasani F, Miraghel SA, Chaleshtori SR, Rezaei-Tazangi F, Beiranvand S, Baziyar P, Manavi MS, Zarrabi A, Nabavi N, Ren J, Aref AR. The endocannabinoid system, a new gatekeeper in the pharmacology of human hepatocellular carcinoma.. Environ Res. 2023 Jul 01;228:115914. doi: 10.1016/j.envres.2023.115914. DOI
  57. Almajidi YQ, Kadhim MM, Alsaikhan F, Turki Jalil A, Hassan Sayyid N, Alexis Ram<U+00ED>rez-Coronel A, Hassan Jawhar Z, Gupta J, Nabavi N, Yu W, Ertas YN. Doxorubicin-loaded micelles in tumor cell-specific chemotherapy.. Environ Res. 2023 Jun 15;227:115722. doi: 10.1016/j.envres.2023.115722. DOI
  58. Hashemi M, Zandieh MA, Ziaolhagh S, Mojtabavi S, Sadi FH, Koohpar ZK, Ghanbarirad M, Haghighatfard A, Behroozaghdam M, Khorrami R, Nabavi N, Ren J, Reiter RJ, Salimimoghadam S, Rashidi M, Hushmandi K, Taheriazam A, Entezari M. Nrf2 signaling in diabetic nephropathy, cardiomyopathy and neuropathy: Therapeutic targeting, challenges and future prospective.. Biochim Biophys Acta Mol Basis Dis. 2023 Jun;1869(5):166714. doi: 10.1016/j.bbadis.2023.166714. DOI
  59. Hashemi M, Sabouni E, Rahmanian P, Entezari M, Mojtabavi M, Raei B, Zandieh MA, Behroozaghdam M, Mirzaei S, Hushmandi K, Nabavi N, Salimimoghadam S, Ren J, Rashidi M, Raesi R, Taheriazam A, Alexiou A, Papadakis M, Tan SC. Deciphering STAT3 signaling potential in hepatocellular carcinoma: tumorigenesis, treatment resistance, and pharmacological significance.. Cell Mol Biol Lett. 2023 Apr 21;28(1):33. doi: 10.1186/s11658-023-00438-9. DOI
  60. Sabouni E, Nejad MM, Mojtabavi S, Khoshduz S, Mojtabavi M, Nadafzadeh N, Nikpanjeh N, Mirzaei S, Hashemi M, Aref AR, Khorrami R, Nabavi N, Ertas YN, Salimimoghadam S, Zandieh MA, Rahmanian P, Taheriazam A, Hushmandi K. Unraveling the function of epithelial-mesenchymal transition (EMT) in colorectal cancer: Metastasis, therapy response, and revisiting molecular pathways.. Biomed Pharmacother. 2023 Apr;160:114395. doi: 10.1016/j.biopha.2023.114395. DOI
  61. Hashemi M, Zandieh MA, Talebi Y, Rahmanian P, Shafiee SS, Nejad MM, Babaei R, Sadi FH, Rajabi R, Abkenar ZO, Rezaei S, Ren J, Nabavi N, Khorrami R, Rashidi M, Hushmandi K, Entezari M, Taheriazam A. Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.. Biomed Pharmacother. 2023 Apr;160:114392. doi: 10.1016/j.biopha.2023.114392. DOI
  62. Hashemi M, Mirdamadi MSA, Talebi Y, Khaniabad N, Banaei G, Daneii P, Gholami S, Ghorbani A, Tavakolpournegari A, Farsani ZM, Zarrabi A, Nabavi N, Zandieh MA, Rashidi M, Taheriazam A, Entezari M, Khan H. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents.. Pharmacol Res. 2023 Jan;187:106568. doi: 10.1016/j.phrs.2022.106568. DOI
  63. Hashemi M, Hasani S, Hajimazdarany S, Mirmazloomi SR, Makvandy S, Zabihi A, Goldoost Y, Gholinia N, Kakavand A, Tavakolpournegari A, Salimimoghadam S, Nabavi N, Zarrabi A, Taheriazam A, Entezari M, Hushmandi K. Non-coding RNAs targeting notch signaling pathway in cancer: From proliferation to cancer therapy resistance.. Int J Biol Macromol. 2022 Dec 01;222(Pt A):1151-1167. doi: 10.1016/j.ijbiomac.2022.09.203. DOI
  64. Nann P, Nabavi N, Ziafat K, Preston R, Chau A, Krausz MR, Schwarz SKW, Maclure M. Trends in opioid dispensing after common abdominal and orthopedic surgery procedures in British Columbia: a retrospective cohort analysis.. Can J Anaesth. 2022 Aug;69(8):986-996. doi: 10.1007/s12630-022-02272-7. DOI
  65. Ziafat K, Polderman S, Nabavi N, Preston R, Chau A, Krausz MR, Schwarz SKW, Maclure M. Opioid dispensing after Cesarean delivery in British Columbia: a historical cohort analysis from 2004 to 2019.. Can J Anaesth. 2022 Aug;69(8):997-1006. doi: 10.1007/s12630-022-02271-8. DOI
  66. Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y. Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention.. J Exp Clin Cancer Res. 2022 Jul 01;41(1):214. doi: 10.1186/s13046-022-02406-1. DOI
  67. Entezari M, Ghanbarirad M, Taheriazam A, Sadrkhanloo M, Zabolian A, Goharrizi MASB, Hushmandi K, Aref AR, Ashrafizadeh M, Zarrabi A, Nabavi N, Rabiee N, Hashemi M, Samarghandian S. Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling.. Biomed Pharmacother. 2022 Jun;150:112963. doi: 10.1016/j.biopha.2022.112963. DOI
  68. Madamsetty VS, Mohammadinejad R, Uzieliene I, Nabavi N, Dehshahri A, Garc<U+00ED>a-Couce J, Tavakol S, Moghassemi S, Dadashzadeh A, Makvandi P, Pardakhty A, Aghaei Afshar A, Seyfoddin A. Dexamethasone: Insights into Pharmacological Aspects, Therapeutic Mechanisms, and Delivery Systems.. ACS Biomater Sci Eng. 2022 May 09;8(5):1763-1790. doi: 10.1021/acsbiomaterials.2c00026. DOI
  69. Mirzaei S, Gholami MH, Hushmandi K, Hashemi F, Zabolian A, Canadas I, Zarrabi A, Nabavi N, Aref AR, Crea F, Wang Y, Ashrafizadeh M, Kumar AP. Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer.. J Hematol Oncol. 2022 May 06;15(1):50. doi: 10.1186/s13045-022-01276-6. DOI
  70. Ashrafizadeh M, Paskeh MDA, Mirzaei S, Gholami MH, Zarrabi A, Hashemi F, Hushmandi K, Hashemi M, Nabavi N, Crea F, Ren J, Klionsky DJ, Kumar AP, Wang Y. Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.. J Exp Clin Cancer Res. 2022 Mar 22;41(1):105. doi: 10.1186/s13046-022-02293-6. DOI
  71. Mirzaei S, Gholami MH, Hushmandi K, Hashemi F, Zabolian A, Canadas I, Zarrabi A, Nabavi N, Aref AR, Crea F, Wang Y, Ashrafizadeh M, Kumar AP. The long and short non-coding RNAs modulating EZH2 signaling in cancer.. J Hematol Oncol. 2022 Mar 02;15(1):18. doi: 10.1186/s13045-022-01235-1. DOI
  72. Ashrafizadeh M, Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Raei M, Hushmandi K, Zarrabi A, Voelcker NH, Aref AR, Hamblin MR, Varma RS, Samarghandian S, Arostegi IJ, Alzola M, Kumar AP, Thakur VK, Nabavi N, Makvandi P, Tay FR, Orive G. Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression.. Carbohydr Polym. 2021 Nov 15;272:118491. doi: 10.1016/j.carbpol.2021.118491. DOI
  73. Ashrafizadeh M, Zarrabi A, Mirzaei S, Hashemi F, Samarghandian S, Zabolian A, Hushmandi K, Ang HL, Sethi G, Kumar AP, Ahn KS, Nabavi N, Khan H, Makvandi P, Varma RS. Gallic acid for cancer therapy: Molecular mechanisms and boosting efficacy by nanoscopical delivery.. Food Chem Toxicol. 2021 Nov;157:112576. doi: 10.1016/j.fct.2021.112576. DOI
  74. Oo HZ, Lohinai Z, Khazamipour N, Lo J, Kumar G, Pihl J, Adomat H, Nabavi N, Behmanesh H, Zhai B, Dagil R, Choudhary S, Gustavsson T, Clausen TM, Esko JD, Allen JW, Thompson MA, Tran NL, Moldvay J, Dome B, Salanti A, Al-Nakouzi N, Weiss GJ, Daugaard M. Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer.. Cancers (Basel). 2021 Sep 06;13(17). doi: 10.3390/cancers13174489. DOI
  75. Ashrafizadeh M, Zarrabi A, Orouei S, Zabolian A, Saleki H, Azami N, Bejandi AK, Mirzaei S, Janaghard MN, Hushmandi K, Nabavi N, Baradaran B, Kumar AP, Makvandi P, Samarghandian S, Khan H, Hamblin MR. Interplay between SOX9 transcription factor and microRNAs in cancer.. Int J Biol Macromol. 2021 Jul 31;183:681-694. doi: 10.1016/j.ijbiomac.2021.04.185. DOI
  76. Mather RL, Parolia A, Carson SE, Venalainen E, Roig-Carles D, Jaber M, Chu SC, Alborelli I, Wu R, Lin D, Nabavi N, Jachetti E, Colombo MP, Xue H, Pucci P, Ci X, Hawkes C, Li Y, Pandha H, Ulitsky I, Marconett C, Quagliata L, Jiang W, Romero I, Wang Y, Crea F. The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms.. Mol Oncol. 2021 Jul;15(7):1921-1941. doi: 10.1002/1878-0261.12954. DOI
  77. Ashrafizaveh S, Ashrafizadeh M, Zarrabi A, Husmandi K, Zabolian A, Shahinozzaman M, Aref AR, Hamblin MR, Nabavi N, Crea F, Wang Y, Ahn KS. Long non-coding RNAs in the doxorubicin resistance of cancer cells.. Cancer Lett. 2021 Jun 28;508:104-114. doi: 10.1016/j.canlet.2021.03.018. DOI
  78. Mirzaei S, Mohammadi AT, Gholami MH, Hashemi F, Zarrabi A, Zabolian A, Hushmandi K, Makvandi P, Samec M, Liskova A, Kubatka P, Nabavi N, Aref AR, Ashrafizadeh M, Khan H, Najafi M. Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance.. Pharmacol Res. 2021 May;167:105575. doi: 10.1016/j.phrs.2021.105575. DOI
  79. Mirzaei S, Gholami MH, Mahabady MK, Nabavi N, Zabolian A, Banihashemi SM, Haddadi A, Entezari M, Hushmandi K, Makvandi P, Samarghandian S, Zarrabi A, Ashrafizadeh M, Khan H. Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation.. Biomed Pharmacother. 2021 Jan;133:111077. doi: 10.1016/j.biopha.2020.111077. DOI
  80. Ashrafizadeh M, Hushmandi K, Rahmani Moghadam E, Zarrin V, Hosseinzadeh Kashani S, Bokaie S, Najafi M, Tavakol S, Mohammadinejad R, Nabavi N, Hsieh CL, Zarepour A, Zare EN, Zarrabi A, Makvandi P. Progress in Delivery of siRNA-Based Therapeutics Employing Nano-Vehicles for Treatment of Prostate Cancer.. Bioengineering (Basel). 2020 Aug 10;7(3). doi: 10.3390/bioengineering7030091. DOI
  81. Shrestha R, Nabavi N, Volik S, Anderson S, Haegert A, McConeghy B, Sar F, Brahmbhatt S, Bell R, Le Bihan S, Wang Y, Collins C, Churg A. Well-Differentiated Papillary Mesothelioma of the Peritoneum Is Genetically Distinct from Malignant Mesothelioma.. Cancers (Basel). 2020 Jun 13;12(6). doi: 10.3390/cancers12061568. DOI
  82. Shrestha R, Nabavi N, Lin YY, Mo F, Anderson S, Volik S, Adomat HH, Lin D, Xue H, Dong X, Shukin R, Bell RH, McConeghy B, Haegert A, Brahmbhatt S, Li E, Oo HZ, Hurtado-Coll A, Fazli L, Zhou J, McConnell Y, McCart A, Lowy A, Morin GB, Chen T, Daugaard M, Sahinalp SC, Hach F, Le Bihan S, Gleave ME, Wang Y, Churg A, Collins CC. BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma.. Genome Med. 2019 Feb 18;11(1):8. doi: 10.1186/s13073-019-0620-3. DOI
  83. Qu S, Xue H, Dong X, Lin D, Wu R, Nabavi N, Collins CC, Gleave ME, Gout PW, Wang Y. Aneustat (OMN54) has aerobic glycolysis-inhibitory activity and also immunomodulatory activity as indicated by a first-generation PDX prostate cancer model.. Int J Cancer. 2018 Jul 15;143(2):419-429. doi: 10.1002/ijc.31310. DOI
  84. Nabavi N, Wei J, Lin D, Collins CC, Gout PW, Wang Y. Pre-clinical Models for Malignant Mesothelioma Research: From Chemical-Induced to Patient-Derived Cancer Xenografts.. Front Genet. 2018;9:232. doi: 10.3389/fgene.2018.00232. DOI
  85. Choi SYC, Ettinger SL, Lin D, Xue H, Ci X, Nabavi N, Bell RH, Mo F, Gout PW, Fleshner NE, Gleave ME, Collins CC, Wang Y. Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer.. Cancer Med. 2018 Jul;7(7):3385-3392. doi: 10.1002/cam4.1587. DOI
  86. Ramnarine VR, Alshalalfa M, Mo F, Nabavi N, Erho N, Takhar M, Shukin R, Brahmbhatt S, Gawronski A, Kobelev M, Nouri M, Lin D, Tsai H, Lotan TL, Karnes RJ, Rubin MA, Zoubeidi A, Gleave ME, Sahinalp C, Wyatt AW, Volik SV, Beltran H, Davicioni E, Wang Y, Collins CC. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.. Gigascience. 2018 Jun 01;7(6). doi: 10.1093/gigascience/giy050. DOI
  87. Nabavi N, Saidy NRN, Venalainen E, Haegert A, Parolia A, Xue H, Wang Y, Wu R, Dong X, Collins C, Crea F, Wang Y. miR-100-5p inhibition induces apoptosis in dormant prostate cancer cells and prevents the emergence of castration-resistant prostate cancer.. Sci Rep. 2017 Jun 22;7(1):4079. doi: 10.1038/s41598-017-03731-8. DOI
  88. Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y. Metabolic heterogeneity signature of primary treatment-na<U+00EF>ve prostate cancer.. Oncotarget. 2017 Apr 18;8(16):25928-25941. doi: 10.18632/oncotarget.15237. DOI
  89. Nabavi N, Bennewith KL, Churg A, Wang Y, Collins CC, Mutti L. Switching off malignant mesothelioma: exploiting the hypoxic microenvironment.. Genes Cancer. 2016 Nov;7(11-12):340-354. doi: 10.18632/genesandcancer.124. DOI
  90. Kim SM, Wang Y, Nabavi N, Liu Y, Correia MA. Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame.. Drug Metab Rev. 2016 Aug;48(3):405-33. doi: 10.1080/03602532.2016.1195403. DOI
  91. Shin J, He M, Liu Y, Paredes S, Villanova L, Brown K, Qiu X, Nabavi N, Mohrin M, Wojnoonski K, Li P, Cheng HL, Murphy AJ, Valenzuela DM, Luo H, Kapahi P, Krauss R, Mostoslavsky R, Yancopoulos GD, Alt FW, Chua KF, Chen D. SIRT7 represses Myc activity to suppress ER stress and prevent fatty liver disease.. Cell Rep. 2013 Nov 14;5(3):654-665. doi: 10.1016/j.celrep.2013.10.007. DOI
  92. Pustylnik S, Fiorino C, Nabavi N, Zappitelli T, da Silva R, Aubin JE, Harrison RE. EB1 levels are elevated in ascorbic Acid (AA)-stimulated osteoblasts and mediate cell-cell adhesion-induced osteoblast differentiation.. J Biol Chem. 2013 Jul 26;288(30):22096-110. doi: 10.1074/jbc.M113.481515. DOI
  93. Durand M, Komarova SV, Bhargava A, Trebec-Reynolds DP, Li K, Fiorino C, Maria O, Nabavi N, Manolson MF, Harrison RE, Dixon SJ, Sims SM, Mizianty MJ, Kurgan L, Haroun S, Boire G, de Fatima Lucena-Fernandes M, de Brum-Fernandes AJ. Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the In Vitro Osteoclast Differentiation in Arthritis study.. Arthritis Rheum. 2013 Jan;65(1):148-58. doi: 10.1002/art.37722. DOI
  94. Nabavi N, Pustylnik S, Harrison RE. Rab GTPase mediated procollagen trafficking in ascorbic acid stimulated osteoblasts.. PLoS One. 2012;7(9):e46265. doi: 10.1371/journal.pone.0046265. DOI
  95. Nabavi N, Khandani A, Camirand A, Harrison RE. Effects of microgravity on osteoclast bone resorption and osteoblast cytoskeletal organization and adhesion.. Bone. 2011 Nov;49(5):965-74. doi: 10.1016/j.bone.2011.07.036. DOI
  96. Hassanzadeh A, Nitsche M, Armstrong S, Nabavi N, Harrison R, Dixon SJ, Langbein U, Mittler S. Optical waveguides formed by silver ion exchange in Schott SG11 glass for waveguide evanescent field fluorescence microscopy: evanescent images of HEK293 cells.. J Biomed Opt. 2010;15(3):036018. doi: 10.1117/1.3443796. DOI
  97. Nabavi N, Urukova Y, Cardelli M, Aubin JE, Harrison RE. Lysosome dispersion in osteoblasts accommodates enhanced collagen production during differentiation.. J Biol Chem. 2008 Jul 11;283(28):19678-90. doi: 10.1074/jbc.M802517200. DOI

← Back to Publications